US5362718A
(en)
*
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
US5491231A
(en)
*
|
1994-11-28 |
1996-02-13 |
American Home Products Corporation |
Hindered N-oxide esters of rapamycin
|
US5563145A
(en)
*
|
1994-12-07 |
1996-10-08 |
American Home Products Corporation |
Rapamycin 42-oximes and hydroxylamines
|
US7056935B2
(en)
*
|
1995-06-07 |
2006-06-06 |
Gpi Nil Holdings, Inc. |
Rotamase enzyme activity inhibitors
|
US5780462A
(en)
*
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
US6274602B1
(en)
|
1998-06-03 |
2001-08-14 |
Gpi Nil Holdings, Inc. |
Heterocyclic thioester and ketone hair growth compositions and uses
|
US5945441A
(en)
|
1997-06-04 |
1999-08-31 |
Gpi Nil Holdings, Inc. |
Pyrrolidine carboxylate hair revitalizing agents
|
US20010049381A1
(en)
*
|
1997-06-04 |
2001-12-06 |
Gpl Nil Holdings, Inc., |
Pyrrolidine derivative hair growth compositions and uses
|
US6271244B1
(en)
|
1998-06-03 |
2001-08-07 |
Gpi Nil Holdings, Inc. |
N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
|
US6187784B1
(en)
|
1998-06-03 |
2001-02-13 |
Gpi Nil Holdings, Inc. |
Pipecolic acid derivative hair growth compositions and uses
|
US6187796B1
(en)
|
1998-06-03 |
2001-02-13 |
Gpi Nil Holdings, Inc. |
Sulfone hair growth compositions and uses
|
US6429215B1
(en)
|
1998-06-03 |
2002-08-06 |
Gpi Nil Holdings, Inc. |
N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
|
US6274617B1
(en)
*
|
1998-06-03 |
2001-08-14 |
Gpi Nil Holdings, Inc. |
Heterocyclic ester and amide hair growth compositions and uses
|
US6172087B1
(en)
|
1998-06-03 |
2001-01-09 |
Gpi Nil Holding, Inc. |
N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
|
JP2002516839A
(ja)
*
|
1998-06-03 |
2002-06-11 |
ジーピーアイ エヌアイエル ホールディングス, インコーポレイテッド |
ピペコリン酸誘導体毛髪成長組成物およびその使用
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US20050002986A1
(en)
*
|
2000-05-12 |
2005-01-06 |
Robert Falotico |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US6670355B2
(en)
*
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
US6511986B2
(en)
|
2000-08-11 |
2003-01-28 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
MXPA03002258A
(es)
|
2000-09-19 |
2003-06-24 |
Wyeth Corp |
Esteres de rapamicina solubles en agua.
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
JP5100951B2
(ja)
*
|
2000-09-29 |
2012-12-19 |
コーディス・コーポレイション |
被覆医用器具
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
BR0313024A
(pt)
|
2002-07-30 |
2005-07-12 |
Wyeth Corp |
Formulações parenterais contendo um hidroxiéster de rapamicina
|
WO2004060283A2
(fr)
|
2002-12-16 |
2004-07-22 |
Nitromed, Inc. |
Composes a base de rapamycine nitrosee et nitrosylee, compositions et procedes d'utilisation
|
EP2529758A3
(fr)
*
|
2003-01-27 |
2013-01-02 |
Endocyte, Inc. |
Conjugués d'administration de médicaments à liaison au récepteur de vitamines
|
US7349971B2
(en)
*
|
2004-02-05 |
2008-03-25 |
Scenera Technologies, Llc |
System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
|
JP2007532655A
(ja)
*
|
2004-04-14 |
2007-11-15 |
ワイス |
ラパマイシンコンジュゲートおよび抗体のための前駆体である、ジカルボン酸とのラパマイシン42−エステルおよびジカルボン酸とのfk−50632−エステルの調製プロセス
|
MXPA06012404A
(es)
*
|
2004-04-27 |
2007-01-17 |
Wyeth Corp |
Marcado de rapamicina usando metilasas especificas de rapamicina.
|
WO2006115509A2
(fr)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
|
EP1789391B1
(fr)
|
2004-07-23 |
2017-06-28 |
Endocyte, Inc. |
Groupes de liaison bivalents et conjugués de ceux-ci
|
MX2007005153A
(es)
*
|
2004-10-28 |
2007-06-26 |
Wyeth Corp |
Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero.
|
GB0503936D0
(en)
*
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
US20100047338A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
CN101175757B
(zh)
*
|
2005-03-16 |
2012-11-14 |
恩多塞特公司 |
蝶酸及其缀合物的合成和纯化
|
DK2298815T3
(en)
|
2005-07-25 |
2015-06-15 |
Emergent Product Dev Seattle |
B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
|
BRPI0615354A2
(pt)
*
|
2005-08-19 |
2011-05-17 |
Endocyte Inc |
conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
|
EP3488866A1
(fr)
|
2005-11-04 |
2019-05-29 |
Wyeth LLC |
Combinaisons antinéoplasiques avec inhibiteur de mtor, d'herceptine et/ou hki-272
|
AU2006322029A1
(en)
|
2005-12-07 |
2007-06-14 |
Wyeth |
Process for the preparation of purified crystalline CCI-779
|
BRPI0619578A2
(pt)
|
2005-12-07 |
2011-10-04 |
Wyeth Corp |
processo para preparar um 42-éster de rapamicina, composto, método para isolar o boronato do 42-éster de rapamicina bruto a partir do licor mãe, método para purificação de um boronato do 42-éster de rapamicina, e, boronato de cci-779
|
AU2006322030A1
(en)
*
|
2005-12-07 |
2007-06-14 |
Wyeth |
Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
|
US7678901B2
(en)
*
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US8414909B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8440185B2
(en)
*
|
2006-12-26 |
2013-05-14 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
US20090142342A1
(en)
*
|
2006-12-27 |
2009-06-04 |
Johns Hopkins University |
B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
|
EP2109455A2
(fr)
*
|
2006-12-27 |
2009-10-21 |
The Johns Hopkins University |
Compositions et procédés pour la stimulation d'une réaction immunitaire
|
WO2008101231A2
(fr)
|
2007-02-16 |
2008-08-21 |
Endocyte, Inc. |
Procédés et compositions de traitement et de diagnostic d'une maladie rénale
|
CN103948937A
(zh)
|
2007-03-14 |
2014-07-30 |
恩多塞特公司 |
结合配体连接的微管溶素递药缀合物
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
BRPI0812970A2
(pt)
|
2007-06-25 |
2019-09-24 |
Endocyte Inc |
conjugados contendo espaçadores hidrofílicos
|
AU2008287195A1
(en)
*
|
2007-07-06 |
2009-02-19 |
Emergent Product Development Seattle, Llc |
Binding peptides having a C-terminally disposed specific binding domain
|
AU2009225434B2
(en)
*
|
2008-03-21 |
2014-05-22 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
ES2368700T3
(es)
*
|
2008-04-11 |
2011-11-21 |
Emergent Product Development Seattle, Llc |
Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
|
WO2010024898A2
(fr)
|
2008-08-29 |
2010-03-04 |
Lutonix, Inc. |
Procédés et appareils pour poser un revêtement sur des cathéters à ballonnet
|
CA2937492C
(fr)
|
2008-11-11 |
2019-08-13 |
The Board Of Regents Of The University Of Texas System |
Inhibition de cible mammalienne de rapamycine
|
AU2010210422A1
(en)
|
2009-02-05 |
2011-08-18 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
|
IN2012DN02753A
(fr)
|
2009-08-31 |
2015-09-18 |
Amplimmune Inc |
|
CN102770129A
(zh)
|
2009-10-30 |
2012-11-07 |
阿里亚德医药股份有限公司 |
治疗癌症的方法和组合物
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
WO2011109833A2
(fr)
|
2010-03-05 |
2011-09-09 |
President And Fellows Of Harvard College |
Compositions de cellules dendritiques induites et utilisations associées
|
MX342590B
(es)
|
2010-04-27 |
2016-10-05 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
|
EP2532740A1
(fr)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
|
WO2013126797A1
(fr)
|
2012-02-24 |
2013-08-29 |
Purdue Research Foundation |
Ciblage du récepteur de la cholécystokinine de type b pour imagerie et thérapie
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
EP3939572B1
(fr)
|
2012-04-12 |
2024-03-27 |
Yale University |
Véhicules pour l'administration contrôlée d'agents pharmaceutiques différents
|
WO2014059295A1
(fr)
|
2012-10-12 |
2014-04-17 |
The Board Of Regents Of The University Of Texas System |
Utilisation d'inhibiteurs mtor pour traiter le déficit cognitif vasculaire
|
SG11201502896XA
(en)
|
2012-10-16 |
2015-05-28 |
Endocyte Inc |
Drug delivery conjugates containing unnatural amino acids and methods for using
|
EP2914260A1
(fr)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Procédés pour prévenir le syndrome des antiphospholipides (sapl)
|
EP2934575A2
(fr)
|
2012-12-19 |
2015-10-28 |
Amplimmune, Inc. |
Anticorps spécifiques de b7-h4, compositions et utilisations de ceux-ci
|
WO2014160328A1
(fr)
|
2013-03-13 |
2014-10-02 |
The Board Of Regents Of The University Of Texas System |
Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux
|
CA2904170A1
(fr)
|
2013-03-14 |
2014-09-25 |
University Of Maryland, Baltimore |
Agents de diminution du recepteur des androgenes et leurs utilisations
|
US20160146806A1
(en)
|
2013-05-17 |
2016-05-26 |
Amplimmune, Inc. |
Receptors for b7-h4
|
WO2015023710A1
(fr)
|
2013-08-12 |
2015-02-19 |
Tokai Pharmaceuticals, Inc. |
Biomarqueurs pour le traitement de troubles néoplasiques à l'aide de thérapies ciblant les androgènes
|
AU2014373683B2
(en)
|
2013-12-31 |
2020-05-07 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
EP3122376A4
(fr)
|
2014-03-27 |
2017-12-20 |
The Brigham and Women's Hospital, Inc. |
Conjugués de médicaments activés métaboliquement pour vaincre la résistance dans une thérapie du cancer
|
EP3131546B1
(fr)
|
2014-04-16 |
2022-02-16 |
Rapamycin Holdings, Inc. |
Préparation orale de rapamycine pour utilisation dans le traitement de la gingivo-stomatite chronique féline (fcgs)
|
EP3148564B1
(fr)
|
2014-06-02 |
2020-01-08 |
Children's Medical Center Corporation |
Procédés et compositions pour une immunomodulation
|
CN105461738B
(zh)
|
2014-06-03 |
2019-03-08 |
中国人民解放军军事医学科学院毒物药物研究所 |
一种雷帕霉素衍生物、其制备方法、其药物组合物及用途
|
WO2016040806A1
(fr)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
Inhibiteurs de mtorc1
|
WO2017029391A1
(fr)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nouvelle méthode de traitement du cancer
|
ES2957882T3
(es)
|
2015-09-04 |
2024-01-29 |
Univ Yale |
Nanocomposiciones de ácidos biliares poliméricos dirigidas al páncreas y al colon
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
RU2757394C2
(ru)
|
2016-08-03 |
2021-10-14 |
Нексткьюр, Инк. |
Композиции и способы для модуляции передачи сигнала lair
|
EP4360714A2
(fr)
|
2016-09-21 |
2024-05-01 |
Nextcure, Inc. |
Anticorps pour siglec-15 et leurs procédés d'utilisation
|
US11390675B2
(en)
|
2016-09-21 |
2022-07-19 |
Nextcure, Inc. |
Antibodies for Siglec-15 and methods of use thereof
|
EP3848065B1
(fr)
|
2017-05-15 |
2023-07-26 |
C. R. Bard, Inc. |
Dispositif médical à revêtement d'élution de médicament et à couche intermédiaire
|
WO2019002168A1
(fr)
|
2017-06-26 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes et compositions pharmaceutiques de traitement du syndrome d'olmsted
|
JP2020527044A
(ja)
|
2017-07-13 |
2020-09-03 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
CD8+CD45RCLOW/−Treg集団の拡大増殖および免疫抑制能力を高めるための方法
|
SG11202010560QA
(en)
|
2018-05-01 |
2020-11-27 |
Revolution Medicines Inc |
C26-linked rapamycin analogs as mtor inhibitors
|
SG11202010559UA
(en)
|
2018-05-01 |
2020-11-27 |
Revolution Medicines Inc |
C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
|
US20210115378A1
(en)
|
2018-05-09 |
2021-04-22 |
Yale University |
Compositions and systems for ex vivo cell modulation and methods of use thereof
|
WO2019217552A1
(fr)
|
2018-05-09 |
2019-11-14 |
Yale University |
Particules pour la libération spatio-temporelle d'agents
|
AU2019310040A1
(en)
|
2018-07-23 |
2021-02-11 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
AU2019310039A1
(en)
|
2018-07-23 |
2021-02-18 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
WO2020053125A1
(fr)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Procédés de traitement de la neurofibromatose
|
US11541152B2
(en)
|
2018-11-14 |
2023-01-03 |
Lutonix, Inc. |
Medical device with drug-eluting coating on modified device surface
|
EP3911302A1
(fr)
|
2019-01-17 |
2021-11-24 |
Georgia Tech Research Corporation |
Systèmes d'administration de médicament contenant des cholestérols oxydés
|
JP7487228B2
(ja)
|
2019-04-08 |
2024-05-20 |
バード・ペリフェラル・バスキュラー・インコーポレーテッド |
改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
|
KR20220011123A
(ko)
|
2019-04-11 |
2022-01-27 |
엔클리어 테라피스, 인크. |
뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
|
EP4167958A1
(fr)
|
2020-06-19 |
2023-04-26 |
Yale University |
Nanoparticules d'ester d'acide biliaire polymère comprenant un agent immunomodulateur pour induire une tolérance spécifique à l'antigène
|
EP4370160A1
(fr)
|
2021-07-15 |
2024-05-22 |
President And Fellows Of Harvard College |
Compositions et méthodes associées à des cellules comprenant des particules adhérées
|
WO2024008799A1
(fr)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Méthodes de traitement de la glomérulonéphrite proliférative
|
WO2024028433A1
(fr)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Procédés de traitement de troubles lymphoprolifératifs
|